CT SCAN BIPHASIC, CCT LIVER (DELDC) at Dr. Essa Lab

CT SCAN BIPHASIC, CCT LIVER (DELDC) at Dr. Essa Lab

The CT SCAN BIPHASIC, CCT LIVER (DELDC) at Dr. Essa Lab is a highly specialized, non-invasive diagnostic imaging procedure designed to evaluate the liver parenchyma, its complex dual vascular supply, and associated hepatobiliary structures with exceptional anatomical precision. Utilizing state-of-the-art Multidetector Computed Tomography (MDCT) technology, this advanced scan plays a pivotal role in modern hepatology, gastroenterology, and oncology. By capturing high-resolution cross-sectional images of the abdomen during specific physiological phases of contrast circulation, the biphasic CT scan allows consultant radiologists to differentiate between benign and malignant liver lesions, assess vascular patency, and diagnose chronic liver diseases with high diagnostic accuracy.

To understand the clinical significance of a biphasic CT scan of the liver, it is essential to understand the unique dual blood supply of this vital organ. Unlike most organs that receive oxygenated blood solely from an artery, the liver receives approximately 75% of its blood supply from the portal vein and only 25% from the hepatic artery. However, primary hepatic malignancies, such as Hepatocellular Carcinoma (HCC), and hypervascular metastatic tumors derive nearly 100% of their blood supply from the hepatic artery. This physiological difference is the foundation of multiphasic imaging. By administering an intravenous iodinated contrast agent and scanning the liver at precise intervals, the CT SCAN BIPHASIC, CCT LIVER (DELDC) captures the liver during two distinct phases: the late arterial phase and the portal venous phase. This precise timing allows for the detection of subtle vascular abnormalities and tissue changes that would otherwise remain invisible on a standard, single-phase abdominal CT scan.

At Dr. Essa Lab, this advanced imaging modality is performed using modern CT scanners equipped with low-dose radiation protocols, ensuring patient safety while maintaining superior image quality. The diagnostic value of this scan is immense, particularly in the early detection of liver cancer, the characterization of focal liver lesions (such as hemangiomas, focal nodular hyperplasia, and adenomas), the evaluation of liver cirrhosis, and the pre-operative planning for liver resections or liver transplantation. By providing detailed anatomical and vascular maps, the CT SCAN BIPHASIC, CCT LIVER (DELDC) at Dr. Essa Lab empowers clinicians to make timely, evidence-based treatment decisions, ultimately improving patient outcomes across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is critical to ensure the safety, diagnostic accuracy, and success of the CT SCAN BIPHASIC, CCT LIVER (DELDC) at Dr. Essa Lab. Patients are advised to adhere strictly to the following pre-procedure guidelines:

• Fasting Requirements: Patients must fast (no solid food or liquids other than plain water) for at least 4 to 6 hours prior to the scheduled scan. This ensures that the stomach and upper gastrointestinal tract are empty, minimizing motion artifacts and reducing the risk of nausea or vomiting during contrast administration.
• Kidney Function Assessment: Because this procedure requires the intravenous administration of an iodinated contrast medium, patients must present a recent Serum Creatinine and Estimated Glomerular Filtration Rate (eGFR) report (ideally performed within the last 30 days). This is essential to evaluate renal function and prevent Contrast-Induced Nephropathy (CIN).
• Allergy History: Patients must inform the clinical staff of any history of allergies, particularly to iodine, contrast media, shellfish, or specific medications. If a prior mild allergic reaction occurred, a pre-medication protocol involving antihistamines and corticosteroids may be prescribed by the referring physician.
• Medication Management: Most daily medications can be taken with small sips of water. However, diabetic patients taking Metformin must consult their physician, as this medication may need to be temporarily discontinued for 48 hours after the contrast injection to prevent lactic acidosis, depending on their renal function.
• Hydration: Adequate hydration before and after the scan is highly recommended. Drinking plenty of water helps flush the contrast medium out of the kidneys efficiently after the procedure.
• Clothing and Personal Items: Patients should wear loose, comfortable clothing. All metallic objects, including jewelry, belts, zippers, and body piercings, must be removed before the scan, as metal causes severe streak artifacts on CT images.

During the Procedure

The CT SCAN BIPHASIC, CCT LIVER (DELDC) is a streamlined, highly coordinated procedure designed to maximize patient comfort and diagnostic yield. Here is a detailed breakdown of what occurs during the scan:

• Initial Assessment and IV Cannulation: Upon arrival at Dr. Essa Lab, the clinical team will review the patient’s medical history, allergy profile, and renal function reports. A high-quality intravenous (IV) cannula (usually 18G or 20G) will be placed in a large vein in the antecubital fossa of the arm. This large-bore cannula is necessary to accommodate the rapid injection rate of the contrast agent via an automated power injector.
• Patient Positioning: The patient is escorted to the CT scan room and positioned supine (lying on their back) on the motorized CT examination table. The technologist will place comfortable straps to help the patient remain perfectly still, as even minor movement can blur the high-resolution images. The patient’s arms are typically raised above their head to prevent beam-hardening artifacts across the abdomen.
• The CT Gantry and Scanner: The table will slowly slide into the large, doughnut-shaped CT gantry. The technologist will operate the equipment from an adjacent control room, maintaining constant visual contact and communication with the patient through an intercom system.
• Contrast Administration and Scanning Phases: An initial, non-contrast scout scan is performed to plan the exact imaging limits. Next, the automated power injector administers the iodinated contrast medium at a precise flow rate (typically 3 to 5 mL per second). As the contrast enters the bloodstream, the scanner captures two primary phases:
• Late Arterial Phase (approx. 30-35 seconds post-injection): This phase captures the peak enhancement of the hepatic artery and hypervascular liver lesions.
• Portal Venous Phase (approx. 70-80 seconds post-injection): This phase highlights the portal venous system and the normal liver parenchyma, allowing for the identification of hypovascular lesions and tumor washout.
• Patient Experience: During the contrast injection, patients commonly experience a warm, flushing sensation throughout their body, a metallic taste in their mouth, or the temporary sensation of needing to urinate. These are completely normal, transient side effects that resolve within a few minutes.
• Breath-Hold Instructions: To eliminate respiratory motion artifacts, the automated system or technologist will instruct the patient to take a deep breath and hold it for approximately 10 to 15 seconds during each scanning phase.
• Duration and Safety: The actual scanning process takes less than 10 minutes, though the entire visit may take 30 to 45 minutes to allow for preparation and post-procedure observation. The radiation dose is carefully optimized using advanced iterative reconstruction technologies.

When is a CT SCAN BIPHASIC, CCT LIVER (DELDC) Performed?

Characterization of Focal Liver Lesions

Physicians frequently request a biphasic CT scan when an ultrasound or standard CT scan reveals an indeterminate mass or lesion within the liver. Because different liver lesions exhibit distinct vascular enhancement patterns during the arterial and portal venous phases, this scan is crucial for differentiating benign lesions, such as hemangiomas, focal nodular hyperplasia (FNH), and hepatic adenomas, from malignant tumors like Hepatocellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma. Accurate characterization prevents unnecessary invasive biopsies and guides appropriate clinical management.

Surveillance and Diagnosis of Hepatocellular Carcinoma (HCC)

For patients with known chronic liver diseases, such as Hepatitis B, Hepatitis C, or non-alcoholic steatohepatitis (NASH), who are at high risk for developing Hepatocellular Carcinoma, the CT SCAN BIPHASIC, CCT LIVER (DELDC) serves as a gold-standard diagnostic tool. HCC is a highly vascular tumor that classically demonstrates intense enhancement during the late arterial phase (arterial hyperenhancement) followed by rapid contrast clearance during the portal venous phase (washout). Detecting these specific dynamics allows for a definitive diagnosis of HCC without the need for a tissue biopsy in high-risk patients.

Evaluation of Metastatic Liver Disease

The liver is one of the most common sites for cancer metastasis, particularly from primary malignancies of the gastrointestinal tract, breast, lung, and pancreas. Oncologists request a biphasic CT scan of the liver to detect, stage, and monitor metastatic lesions. While some metastases are hypervascular and show up clearly in the arterial phase, others are hypovascular and are best visualized as dark, non-enhancing areas against the brightly enhancing normal liver tissue during the portal venous phase. This comprehensive evaluation is vital for accurate cancer staging and treatment planning.

Pre-Surgical Planning and Liver Transplant Evaluation

Before a patient undergoes major hepatic surgery, such as a segmentectomy, lobectomy, or liver transplantation, surgeons require a detailed anatomical map of the liver and its blood vessels. The CT SCAN BIPHASIC, CCT LIVER (DELDC) provides high-resolution, three-dimensional vascular reconstructions of the hepatic arteries, portal veins, and hepatic veins. This allows surgical teams to assess vascular anatomy, identify anatomical variants, calculate segmental liver volumes (volumetry), and plan precise surgical margins, significantly reducing the risk of intraoperative complications.

Assessment of Portal Hypertension and Vascular Patency

In patients suffering from advanced liver cirrhosis, portal hypertension can lead to severe complications, including variceal bleeding, ascites, and splenomegaly. Clinicians utilize the biphasic CT scan to evaluate the patency of the portal vein, hepatic veins, and inferior vena cava. It is highly effective in detecting portal vein thrombosis (clots), Budd-Chiari syndrome (hepatic vein obstruction), and the development of collateral venous pathways (varices), providing critical information for managing portal hypertension and planning interventions like TIPS (Transjugular Intrahepatic Portosystemic Shunt).

What Does a CT SCAN BIPHASIC, CCT LIVER (DELDC) Detect?

The CT SCAN BIPHASIC, CCT LIVER (DELDC) is capable of detecting a wide spectrum of pathological conditions affecting the liver, its vasculature, and surrounding abdominal structures. Key diagnostic findings include:

• Hepatocellular Carcinoma (HCC): Characterized by intense, heterogeneous enhancement during the arterial phase and rapid washout during the portal venous phase.
• Hepatic Hemangioma: The most common benign liver tumor, showing peripheral, globular, discontinuous enhancement in the arterial phase with progressive centripetal fill-in.
• Focal Nodular Hyperplasia (FNH): A benign lesion demonstrating rapid, intense, homogeneous arterial enhancement, often with a non-enhancing central stellate scar.
• Hepatic Adenoma: A benign, hypervascular tumor associated with oral contraceptive use, showing early arterial enhancement and variable washout, with a risk of hemorrhage.
• Hypervascular Metastases: Secondary tumors (e.g., from neuroendocrine tumors, thyroid cancer, or melanoma) that enhance intensely during the arterial phase.
• Hypovascular Metastases: Secondary tumors (e.g., from colorectal or pancreatic cancer) that appear hypodense relative to the liver parenchyma in the portal venous phase.
• Liver Cirrhosis: Characterized by a nodular liver surface, hypertrophy of the caudate and left lobes, atrophy of the right lobe, and widening of the fissures.
• Portal Vein Thrombosis: A partial or complete filling defect within the portal vein, indicating a blood clot or tumor thrombus.
• Budd-Chiari Syndrome: Thrombosis or obstruction of the hepatic veins, presenting with hepatomegaly, caudate lobe hypertrophy, and delayed patchy liver enhancement.
• Hepatic Steatosis (Fatty Liver): Diffuse or focal reduction in liver attenuation, making the liver parenchyma appear darker than the spleen on non-contrast or portal venous phases.
• Hepatic Abscess: A localized collection of pus, appearing as a low-attenuation fluid collection with a thick, contrast-enhancing rim (the